Chelsea Therapeutics International Inc. delivered unhappy news Monday morning, acknowledging the FDA had raised questions about safety and efficacy in a briefing document released in advance of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting on the new drug application (NDA) for lead candidate Northera (droxidopa), scheduled for Feb. 23.